Advanced age, cardiovascular risk burden, and timed up and go test performance in Parkinson disease
- PMID: 24864306
- PMCID: PMC4296117
- DOI: 10.1093/gerona/glu070
Advanced age, cardiovascular risk burden, and timed up and go test performance in Parkinson disease
Abstract
Background: Cardiovascular comorbidities are a known risk factor for impaired mobility in elderly individuals. Motor impairments in Parkinson disease are conventionally ascribed to nigrostriatal dopaminergic denervation although progressive gait and balance impairments become more common with aging and often show limited response to dopaminergic replacement therapies.
Methods: We explored the association between elevated cardiovascular risk factors and performance on the Timed Up and Go test in cross-sectional of Parkinson disease subjects (n = 83). Cardiovascular risk factor status was estimated using the Framingham General Cardiovascular Disease risk-scoring algorithm in order to dichotomize the cohort into those with and without elevated modifiable cardiovascular risk compared with normative scores for age and gender. All subjects underwent clinical and neuroimaging evaluations including a 3-m Timed Up and Go test, [(11)C]dihydrotetrabenazine positron emission tomography imaging to estimate nigrostriatal dopamine terminal loss, and an magnetic resonance imaging assessment of leukoaraiosis. A similar analysis was performed in 49 healthy controls.
Results: After adjusting for disease duration, leukoaraiosis, and nigrostriatal dopaminergic denervation, Parkinson disease subjects with elevated Framingham risk scores (n = 61) displayed slower Timed Up and Go test performance (β = 1.86, t = 2.41, p = .018) compared with subjects with normal range Framingham risk scores (n = 22). When age ≥65 was added to the model in a post hoc analysis, the strength of effect seen with older age (β = 1.51, t = 2.44, p = .017) was similar to that of elevated Framingham risk scoring (β = 1.87, t = 2.51, p = .014). In a multivariable regression model studying the healthy control population, advanced age (t = 2.15, p = .037) was a significant predictor of Timed Up and Go speed though striatal [(11)C]dihydrotetrabenazine (t = -1.30, p = .19) and elevated Framingham risk scores (t = 1.32, p = .19) were not.
Conclusions: Modifiable cardiovascular risk factors and older age may independently exacerbate balance-related disability in Parkinson disease and may exert additive or synergistic pathological effects. The pathophysiology of these impairments cannot be explained completely by nigrostriatal dopaminergic denervation or leukoaraiosis burden and may relate to systemic factors seen with accelerated aging.
Keywords: Aging; Cardiovascular risk factors.; Dopamine; Framingham risk score; Parkinson disease.
© The Author 2014. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease.Neurology. 2014 Apr 29;82(17):1514-20. doi: 10.1212/WNL.0000000000000356. Epub 2014 Mar 28. Neurology. 2014. PMID: 24682965 Free PMC article.
-
Diabetes is associated with postural instability and gait difficulty in Parkinson disease.Parkinsonism Relat Disord. 2013 May;19(5):522-6. doi: 10.1016/j.parkreldis.2013.01.016. Epub 2013 Feb 23. Parkinsonism Relat Disord. 2013. PMID: 23462483 Free PMC article.
-
Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.Brain. 2011 Aug;134(Pt 8):2358-65. doi: 10.1093/brain/awr139. Epub 2011 Jun 8. Brain. 2011. PMID: 21653540 Free PMC article.
-
Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: an in vivo positron emission tomography study.Mov Disord. 2014 Aug;29(9):1118-24. doi: 10.1002/mds.25929. Epub 2014 Jun 7. Mov Disord. 2014. PMID: 24909584 Free PMC article.
-
Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.Neurophysiol Clin. 2001 Oct;31(5):321-40. doi: 10.1016/s0987-7053(01)00273-8. Neurophysiol Clin. 2001. PMID: 11817273 Review.
Cited by
-
Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.Drugs Aging. 2019 Jun;36(6):511-530. doi: 10.1007/s40266-019-00654-z. Drugs Aging. 2019. PMID: 30937878 Review.
-
Peripheral neuropathy is associated with more frequent falls in Parkinson's disease.Parkinsonism Relat Disord. 2018 Sep;54:46-50. doi: 10.1016/j.parkreldis.2018.04.006. Epub 2018 Apr 3. Parkinsonism Relat Disord. 2018. PMID: 29625874 Free PMC article.
-
Mobile Computing Technologies for Health and Mobility Assessment: Research Design and Results of the Timed Up and Go Test in Older Adults.Sensors (Basel). 2020 Jun 19;20(12):3481. doi: 10.3390/s20123481. Sensors (Basel). 2020. PMID: 32575650 Free PMC article.
-
l-DOPA and Freezing of Gait in Parkinson's Disease: Objective Assessment through a Wearable Wireless System.Front Neurol. 2017 Aug 14;8:406. doi: 10.3389/fneur.2017.00406. eCollection 2017. Front Neurol. 2017. PMID: 28855889 Free PMC article.
-
Dopamine transporter availability in clinically normal aging is associated with individual differences in white matter integrity.Hum Brain Mapp. 2016 Feb;37(2):621-31. doi: 10.1002/hbm.23054. Epub 2015 Nov 6. Hum Brain Mapp. 2016. PMID: 26542307 Free PMC article.
References
-
- Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab. 2006;26:1198–1212. - PubMed
-
- Evans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson’s disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry. 2011;82:1112–1118. 10.1136/jnnp.2011.240366 - PubMed
-
- Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord. 2006;21:1123–1130. - PubMed
-
- Auyeung M, Tsoi TH, Mok V, et al. Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson’s disease patients. J Neurol Neurosurg Psychiatry. 2012;83:607–611. 10.1136/jnnp-2011-301590 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical